Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ocular diseases
Biotech
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
After an FDA rejection last year, Aldeyra has scored a(nother) phase 3 win for dry eye drug reproxalap.
Gabrielle Masson
Aug 8, 2024 10:48am
Aldeyra forewarns potential FDA rejection for dry eye med
Oct 16, 2023 2:49pm
Editas shelves lead asset after disappointing phase 1/2 data
Nov 17, 2022 10:22am
Intellia expands ocular pipeline with 10% stake in SparingVision
Oct 13, 2021 7:00am
Visus, with one drug chasing AbbVie, inks deals to grow pipeline
Aug 19, 2021 8:35am
Immunocore gets FDA breakthrough nod for eye melanoma drug
Feb 19, 2021 8:45am
